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A B S T R A C T
Introduction: Peripheral T-cell lymphomas represent a rare, heterogeneous group of nodal and extra-
nodal mature T-cell lymphomas. Among those, the subtype of PTCL not otherwise speciﬁed (PTCL-NOS)
account for about 25% of all PTCL. While other PTCL subtypes are increasingly recognized as discrete en-
tities based on speciﬁc genotypic and phenotypic alterations, the diagnosis of PTCL-NOS is currently
performed on an “exclusion criteria” model, since PTCL-NOS lack pathognomonic features.
Methods: In this review, we describe the classical pathological features of PTCL-NOS and integrate them
with the most recent molecular ﬁndings.
Results: Thanks to gene expression proﬁling and next generation sequencing approaches, we have re-
cently improved our knowledge of PTCL in general and PTCL-NOS in particular. Indeed, speciﬁc patterns
of gene expression were reported to segregate PTCL into more homogeneous subtypes associated with
distinct clinical outcome. Furthermore, we describe how immunophenotypic, expression and muta-
tional data helped to better deﬁne a new subgroup of PTCL-NOS displaying a global proﬁle close to T
Follicular Helper cell elements. Finally, we review how these new acquisitions are changing the current
diagnostic approach to PTCL-NOS, and how phenotypic features and oncogenic pathways operative in
these lymphomas are becoming targets of novel treatments.
Conclusion: Although no recurrent and speciﬁc biological aberrations have been discovered yet, novel
integrated genomic and transcriptomics approaches are signiﬁcantly improving our knowledge of PTCL
biology and support the development of new powerful diagnostic and prognostic markers, as well as targets
of future therapies.
© 2016 The Authors. Published by Elsevier Ltd on behalf of The Royal College of Pathologists. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/
).
1. Introduction
Peripheral T-cell lymphomas (PTCL) represent a relatively rare disease that account approximately for 15% of all Non-Hodgkin lym-
phomas in Western countries [1–3].
The current WHO classiﬁcation recognizes several distinct PTCL subtypes, among which the most frequent are angioimmunoblastic lym-
phoma (AITL), anaplastic large T cell lymphoma (ALCL) with or without ALK gene translocations, and PTCL-not otherwise speciﬁed (PTCL-NOS)
(Table 1 and Fig. 1). Overall, these entities encompass approximately 60% of all PTCL [2–5]. With the exception of anaplastic large cell lympho-
maswith ALK translocation, PTCLs are recognized for their aggressive clinical course and poor response to conventional chemotherapy [1,3,6–9].
For many years, the differential diagnosis between PTCL subtypes on pathological morphological, phenotypic and molecular grounds
has posed a great challenge. Aside from ALK-translocated ALCL (ALK pos), which represents to date the only PTCL entity deﬁned by a re-
current chromosomal translocation [2], many different studies aimed at the identiﬁcation of distinctive biological markers of ALK-
negative (ALK neg) ALCL, AITL and PTCL-NOS have largely failed. The diagnostic discordance rate between pathologists still accounts for
about 30% of cases, representing a big issue for the correct diagnosis and treatment of each patient [10]. Several studies have recently
described novel biological features of ALCL and AITL, providing signiﬁcant contributions to the pathological characterization of these en-
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tities. High-throughput techniques such as gene expression proﬁling (GEP) and next generation sequencing (NGS) [11–15] have found
shared genomic and transcriptomic features that justify the existence of ALK-neg ALCL and AITL as distinct clinico-pathological entities,
whereas PTCL-NOS still remains an “orphan” disease, without any pathognomonic feature. For these reasons, a diagnosis of PTCL-NOS is
currently based on an “exclusion criteria” model not deﬁned by speciﬁc morphologic, phenotypic or molecular features, and it is likely
that within this diagnostic group lie distinct PTCL subtypes not yet identiﬁed [4,7,16,17]. In this review, we will discuss the recent ad-
vances on the understanding of the biology of PTCL and we will speciﬁcally focus on the PTCL-NOS subtype where future ﬁndings have
the potential to improve diagnostic markers, change current classiﬁcation criteria and even direct efforts for future therapeutic approaches.
2. Morphology and phenotype
PTCL-NOSs encompass cases that don’t fulﬁll diagnostic criteria for speciﬁc PTCL entities. Therefore, PTCL-NOSs are generally charac-
terized by very heterogeneous histological and immunistochemical (IHC) proﬁles. In fact, the old Working Formulation listed PTCL-NOS
Table 1
WHO 2008 classiﬁcation of mature T cell and NK cell neoplasm.
Leukemic
T-cell prolymphocytic leukemia
T-cell large granular lymphocytic leukemia
Adult T cell leukemia/lymphoma
Aggressive NK cell leukemia
Cutaneous
Mycosis fungoides
Sezary Syndrome
Primary cutaneous CD30+ T-cell lymphoproliferative disorder
Lymphomatoid papulosis
Primary cutaneous anaplastic large-cell lymphoma
Primary cutaneous peripheral T-cell lymphomas rare subtypes
Primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma*
Primary cutaneous gamma-delta T-cell lymphoma
Primary cutaneous small/medium CD4+ T-cell lymphoma*
Extranodal
Hepatosplenic T-cell lymphoma
Subcutaneous panniculitic-like T cell lymphoma
Entheropathy associated T-cell lymphoma
Extra nodal NK/T-cell Lymphomas
Nodal
Peripheral T-cell lymphoma not otherwise speciﬁed
Angioimmunoblastic T-cell lymphoma
Anaplastic large cell lymphoma, ALK+
Anaplastic large cell lymphoma, ALK−*
* These represent provisional entities or provisional subtypes of other neoplasm. Disease
shown in italic are newly included in the 2008 WHO classiﬁcation.
Fig. 1. Relative frequencies of non cutaneous mature T-cell lymphoma subtypes in an adult patient population.
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cases as either diffuse small cleaved, mixed, large cell or immunoblastic lymphomas [5,18]. Lymph node involvement is frequent, as only
13% of cases present with extranodal disease only [19]. The normal lymph node architecture is usually effaced by a paracortical or diffuse
proliferation of small, medium and large atypical cells in variable proportions, admixed with variable degrees of vascular proliferation
and inﬂammatory background of non-neoplastic cells (eosinophils, plasma cells, and histiocytes) [7,20–22]. Differential diagnosis of PTCL-
NOS can be challenging and requires extensive immunophenotyping to exclude AITL, ALK-neg ALCL or Adult T-cell Leukemia/Lymphoma
(ATLL) given the lack of characteristic histological features. Although PTCL-NOSs are usually characterized by speciﬁc aberrant T-cell phe-
notypes (i.e. loss of CD5 and CD7 and expression of CD2, CD3, CD4 and/or CD8, the T-cell receptor (TCR) beta-chain (BetaF1)), all investigated
markers have revealed a very low positive and negative predictive value, that do not help differential diagnosis of PTCL-NOS [7] (Table 2).
PTCL-NOS may show confounding features such as presence of Red-Stemberg-like cells and distinct microenvironment alterations typi-
cally associated with AITL, such as clonal restriction of inﬁltrating B-lymphocytes, sometimes with evidence of Epstein–Barr virus (EBV)
integration, in almost 30% of the cases [4,23–25]. Furthermore, EBV virus is usually negative in tumor cells (detectable only in 5% of cases).
Proliferation rate is usually high and Ki-67 rates exceeding 80% of the tumor cells are associated with a worse prognosis [25–27]. Prompted
by a promising anti-tumoral activity of the anti-CD52 monoclonal antibody Alemtuzumab [28], authors have investigated the prevalence
of CD52 expression among PTCL-NOS and reported it at about 40% of total [2,29]. However, the widely divergent CD52 expression by IHC
has made it quite diﬃcult to reliably identify the CD52+ PTCL-NOS cases across laboratories. Furthermore, the availability of new treat-
ments and the high toxicity of Alemtuzumab have decreased the enthusiasm for this molecule in recent years [30].
Different studies have described potential IHC markers related with overexpression of proteins within PTCL-NOS oncogenic pathways.
One of the most important is the PDGFRA protein that was recently reported to be aberrantly expressed in more than 90% of PTCL-NOS
[31]. Interestingly, PDGFRA is activated by the PDGF-AA ligand secreted by the tumor cells themselves, creating an autocrine stimulation
loop that involved STAT1 and STAT5 activation, resulting in tumor proliferation. Another study has described a high NOTCH1 expression
and activation in more than 50% of PTCL-NOS by IHC, suggesting an involvement of this pathway in mature T-lymphoproliferative disor-
ders [32].While the role of these aberrantly expressed proteins in the differential diagnosis of PTCL spectrum diseases remains to be established,
they may also represent potential targets for known drug classes such tyrosine kinase inhibitors and NOTCH-inhibitors.
The PTCL-NOS heterogeneity was further reﬁned by the introduction, in the last WHO classiﬁcation, of speciﬁc and distinct morpho-
logical variants such as the lymphoepitelioid (Lennert) Lymphoma, the T-zone and the T Follicular Helper (TFH) variants [2]. The latter
was particularly important accounting to approximately 20–41% of PTCL-NOS and encompasses all cases expressing TFH cell markers and
exhibiting some, but not all, of the morphological features of AITL [33–36]. Morphologically, this variant is usually characterized by atyp-
ical clear cells forming intrafollicular aggregates, small nodular aggregates in a background of progressively transformed germinal centers
or enlarged perifollicular zone nodular aggregates surrounding hyperplastic follicles [2,33]. Despite a TFH phenotype, early stage disease,
partial lymph node involvement, lack of enlarged follicular dendritic cell meshworks and lack of prominent high endothelial venules helps
the distinction from typical AITL. In the past, this variant was described by different terms including: perifollicular. intrafollicular, paracortical
nodular and expanded mantle zone [2].
3. CD30+ PTCL-NOS
A hot topic in the ﬁeld of PTCL is currently represented by CD30 expression. It is well known that CD30 is highly expressed in all ALCL
and in a signiﬁcant fraction of PTCL-NOS [2,7,37,38]. Although CD30 staining in PTCL-NOS is typically focal and more variable than that
observed in ALCL, CD30 positivity may make the distinction of PTCL-NOS from ALK-neg ALCL problematic. Furthermore, among a large
series of 376 non-cutaneous PTCLs, CD30 was reported to be expressed in 58% and 63% of PTCL-NOS and AITL, respectively [22]. However
a strong CD30 positivity (>50% of tumor cells) was detected only in 23% and 5% of PTCL-NOS and AITL, respectively (Table 3). Interest-
ingly, gene expression and IHC data suggested that all CD30+ PTCL share distinct biological proﬁle across WHO subgroups [38–41]. In fact,
CD30+ PTCL-NOS and ALK-neg ALCL shared an expression signature that was not present in CD30- PTCL-NOS, and consisted in downregulated
expression of T-cell receptor-associated proximal tyrosine kinases (Lck, Fyn, Itk) and of proteins involved in T-cell differentiation/
activation (CD69, ICOS, CD52, NFATc2), and upregulation of JunB and IRF4 [39]. Interestingly, CD30 has been recently reported to promote
Table 2
Differential diagnosis of nodal peripheral T-cell lymphoma, not otherwise speciﬁed, adapted from WHO 2008 classiﬁcation.
Disease Immunophenotypic features
PTCL-NOS CD4>CD8, Antigen loss frequent (CD7, CD5, CD4/CD8, CD52), CD30+/−, CD56−/+, CD10−, BCL6−, CXCL13−, PD1−
PTCL-NOS TFH CD10+, BCL6+, PD1+ and CXCL13+
AITL CD4+ or mixed CD4/CD8, CD10+/−, BCL6+/−, CXCL13+, PD1+, Hyperplasia of FDC, EBV+, CD20+ B blasts
ATLL CD4+, CD25+, CD7−, CD30−/+, CD15−/+, FoxoP3+/−
ALCL CD30+, ALK+/−, EMA+. CD25+, cytotoxic granules+, CD4+/−, CD3−/+, CD43+
T zone Hyperplasia Mixed CD4/CD8, intact architecture, variable CD25 and CD30, scattered CD20+B cell
Table 3
CD30 ICH expression among PTCLs.
Score 0 (0%) Score 1 (1–25%) Score 2 (25–50%) Score 3 (50–75%) Score 4 (75–100%) Score > 2
ALCL ALK pos [37] 0 0 5% 2% 93% 95%
ALCL ALK neg [38] 0 0 0 0 100% 100%
AITL [37] 37% 47% 10% 5% 0 5%
AITL [38] 51.14% 21.42% 11.9% 9.52% - 9.52%
PTCL-NOS [37] 42% 26% 9% 10% 13% 23%
PTCL-NOS [38] 35.63% 12.64% 20.69% 12.64% 18.39% 31.03%
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IRF4 expression through activation of the NF-kB subunits p52 and RelB [40]. In turn, IRF4 activates MYC in a positive feedback loop that
was also described among ALCLs, suggesting a shared oncogenic pathway [27]. In line with heterogeneity of its expression pattern, the
prognostic value of CD30 expression in PTCL-NOS has raised controversy as well. While reported as a favorable prognostic marker by some
[39], Savage et al. [42] have shown that the survival of patients with high expression of CD30+ (≥80% of tumor cells) was extremely poor
with 5-year overall survival of 19%. Therefore, the clinical relevance of the expression of CD30+ should be investigated in larger cohorts
of patients, stratiﬁed for expression levels.
Clearly, the great interest on CD30 expression is due to the high clinical eﬃcacy of the conjugated monoclonal antibody anti-CD30
Brentuximab Vedotin (BV) in naïve and relapsed PTCL patients [28,32–35]. Interestingly, some reports have suggested that BV may even
be active in IHC negative CD30 cases of DLBCL and PTCL [6,43,44]. The disease-speciﬁc variability in such an effect could be explained by
the speciﬁcs of the inﬂammatory background of each neoplasm, or by the poorly reproducible evaluation of CD30 expression by IHC [6,7,43,45].
While there is an obvious need for biomarkers and standardized techniques that can help predict response to BV, this molecule presently
represents one of the most attractive novel therapeutic opportunities in the ﬁeld.
4. Cytogenetic aberrations
The karyotype of PTCL was ﬁrst evaluated in the 90s by conventional cytogenetic approaches. At the time data were limited by the
rarity of these malignancies in Western countries and interpretation was hampered by issues related to histological classiﬁcation [7]. These
studies have reported the frequent presence of complex karyotypes [20], with distinct recurrent cytogenetic aberrations such as losses in
chromosomes 6q, 13 or 13q, and gains in 7q. Overall, abnormal clones were identiﬁed in 71% of PTCL cases, and 1p36 breakpoints were
observed in almost half of the cases [46–48]. More recently, the spectrum of copy-number abnormalities in PTCL-NOS has been investi-
gated bymeans of microarray-based comparative genomic hybridization (aCGH) and by genome-wide human single nucleotide polymorphism
(SNP) arrays resulting in a much larger and more detailed catalogue of abnormalities, some of which shared by different studies [49–52].
Among these were deletion of the 9p21 region, containing the tumor suppressor locus CDKN2A/B, deletions in 10p11 (ZEB-1) and 17p13
(TP53). Conversely, chromosome regions with recurrent gain were: 1q32–43, 2p15–16 (REL), 7q22, 8q24, 11q14–25, 17q11–21 and 21q11–
21 (NRIP). However, the three main studies showed important differences in prevalence of speciﬁc copy number aberrations suggesting
the low reproducibility of this approach (Table 4).
Table 4
PTCL-NOS copy number aberrations data according with the main next studies.
[52] [50] [49]
Series size 36 51 47
Imbalanced Cases 97% 57% 47%
LOSS
1p31 – 10% –
2q37 – 12% –
5q21 25% – 2%
6q14/6q23 19% 10% –
6q21 31% 10% 8%
6q22 25% – 8%
6q24-qte/6q15-q16 22% – 2%
6q14/6q23 19% –
7p14 – – 36%
8p21 19% – 10%
9p21 31% 31% 13%
10cen-p12 17% 12% 19%
10q23-24 28% 10% –
12q21-q22 28% – –
13q14 – 10% 8%
13q21 36% 21% –
14q11 – 74%
Del17p13 17% 21% 10%
GAIN
1p36 5% – –
1p31 – 10%
1q32-qter 17% – 10%
2p15-16 – – 10%
2q37 – 12% –
3p21, 17% – –
4q21-28 – 14% –
6p25 5% – –
7q22-qter 31% 31% 15%
8q24 19% – 10%
9q33-qter 19% 12% –
11cen-q13 17% – –
11q14.1 – 13.7% 10%
11q23 – – 13%
12p13 8% – –
12q21-q22 – – –
17cen-q21; 25% – 13%
16p 22% 14% –
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Few recurrent translocations have been described in PTCL-NOS. One of the most important and well characterized is the t(5;9)(q33;q22),
causing the overexpression of a chimeric protein where the N-terminus of ITK, a tyrosine kinase required for T-cell development, is fused
to the C-terminus portion of SYK, a non-receptor protein kinase [53]. The resulting ITK-SYK protein retains the N-terminal pleckstrin ho-
mology and proline-rich domains of ITK and the C-terminal kinase domain of SYK. This translocation was found to be associated mainly
with TFH PTCL-NOS, and was not detected in AITL or ALK-neg ALCL, so that it was even proposed as a molecular diagnostic marker de-
ﬁning a distinct PTCL-NOS subgroup [53,54]. Interestingly, further observations have shown high SYK levels by IHC in 133 (94%) PTCL cases,
regardless of the presence of the ITK/SYK translocation, but not in normal T cells [54]. Speciﬁcally, this study revealed SYK overexpression
in 35/35 (100%) AITLs, 62/66 (94%) PTCL-NOS, 6/6 (100%) ALCL ALK-pos, 11/12 (92%) ALCL ALK-neg and 19/22 (86%) of other subtypes,
making it one of the most widely expressed oncogenes in PTCLs. In fact, transgenic expression of the ITK/SYK translocation in mice was
able to recapitulate a disease resembling human PTCL, thus underscoring the relevance of this event for disease pathogenesis [55]. This
evidence, combined with the availability of orally available SYK inhibitors [56,57], suggests that SYK merits further evaluation as a can-
didate target for pharmacologic inhibition in patients with PTCL.
Another translocation associated with PTCL-NOS is the t(6;14) (p25;q11.2), resulting in overexpression of the transcription factor IRF4
under the control of the T-cell receptor-alpha (TCRA) locus [58]. This translocation was detected in 12/169 (7%) PTCL-NOS cases that where
all characterized by distinct clinical features with skin and bone marrow involvement at diagnosis.
A recent paper applying next generation sequencing (NGS) to the detection of gross structural changes in 16 PTCL (including 4 PTCL-NOS)
highlighted recurrent abnormalities involving p53-related genes, including inversions and translocations of the TP63 locus and deletions
of CDKN2A, WWOX, and ANKRD11. In particular, TP63 rearrangements were further validated by FISH in a larger series and were found in
9.4% of PTCL-NOS cases (5/53), characterized by higher CD30 and Ki-67 expression, and inferior survival [59]. Thus suggest that, while
TP53 mutations and/or deletions are quite rare in PTCL and PTCL-NOS compared to other lymphoid malignancies [60,61], disruption of
its pathway is a frequent oncogenic event that may contribute to the frequent treatment failures in this class of lymphomas.
Cytogenetic aberrations in general are therefore frequently involved in PTCL-NOS pathogenesis, and play a pivotal role in their bio-
logical complexities. However, the heterogeneity of the neoplastic inﬁltrate and the inconsistencies in histological PTCL classiﬁcation could
clearly hamper the discovery of recurrent aberration with signiﬁcant prevalence. The use of novel methodologies could provide insights
into the genetic complexity of PTCL-NOS, as recently shown in CTCL and ATLL where whole genome sequencing has highlighted a number
of previously unreported recurrent micro-deletions with clear implications for disease pathogenesis [62,63].
5. Gene expression proﬁling
Gene expression proﬁling (GEP) has been widely used to improve PTCL diagnosis accuracy and to better understand its pathogenesis.
Speciﬁc and robust signatures have been identiﬁed for AITL and ALCL, and this has proven so far to be the best approach to distinguish
those entitles from PTCL-NOS [12,33,39,64–68]. In the largest cohort to date, Iqbal et al. have recently conﬁrmed the power of GEP-
derived expression signatures in assigning each PTCL case to the correct subtype, conﬁrming previous reports [12]. This approach proved
to be superior to standard histology/immunohistochemistry, leading to reclassiﬁcation of a number of patients. As expected, the group
with most reclassiﬁed patients was represented by PTCL-NOS, where 55/150 (37%) were classiﬁed as either AITL (21), ALK-neg ALCL (17),
γδ-PTCL (13) or ATLL (4) (Fig. 2). Conversely, 26/117 (22%) AITL cases were reclassiﬁed as PTCL-NOS based on GEP.
By gene expression proﬁling many groups described a common PTCL-NOS expression proﬁle, more evident in supervised analysis com-
paring PTCL-NOS with other entities (i.e. AITL and ALCL) [34,68–71]. Conversely, when PTCL-NOSs were considered alone, GEP revealed a
Fig. 2. Percentage of reclassiﬁed patients according to gene expression signatures by Iqbal et al. [12]. A total 37% of PTCL-NOS were classiﬁed thought other WHO entities:
(i) AITL (n = 21, 14%); (ii) ALCL ALK-neg (n = 17, 11%); (iii) ATLL (n = 4, 3%); (iv) γδ-PTCL (n = 13, 9%). Twenty-six (22%) AITL cases were not molecularly classiﬁable and changed
to PTCL-NOS.
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signiﬁcant heterogeneity, again reinforcing the notion that discrete entities are still grouped in this category [12,34]. For example, the
existence of a distinct PTCL-NOS sub-group has been postulated that has a poor prognosis and expresses a unique repertoire of tran-
scripts enriched for pathways associated with T-CD8+ cell differentiation [34]. Among these, transcripts encoding cytotoxic molecules and
the transcription factor TBX21, which has a pivotal role in Th1 cell differentiation at the expenses of Th2 cells, and in the development of
CD8+ effector cells (Fig. 3) [72]. A more recent and larger study on reclassiﬁed PTCL-NOS cases conﬁrmed that GEP analysis identiﬁed a
TBX21-overexpressing subgroup (49% of patients), but also reported the presence of a second group (33%) characterized by overexpression
of GATA3 [12]. Although GATA3 and TBX21 gene expression levels showed a signiﬁcant inverse correlation, more than 20% of PTCL-NOS
did not meet criteria for either group and were deﬁned as “unclassiﬁed.” Biological and phenotypic features of these “unclassiﬁed” PTCL-NOS
patients are still unknown. Conversely, the TBX21 group conﬁrmed a cytotoxic proﬁle and signiﬁcant enrichment of IFN- and NFkB-related
gene expression signatures, while samples characterized by overexpression of GATA3 and of its known target genes (CCR4, IL18RA, CXCR7,
IK) were enriched for PI3K-, mTOR- and MYC-related signatures. Furthermore, these patients showed a proﬁle compatible with a T-CD4+
cell origin, where GATA3 is known to have a critical role in differentiation and maturation [64,73]. Contrary to the early study [34], sub-
sequent analyses [12,71] showed that TBX21 overexpression by GEP or IHC was associated with a much better prognosis than GATA3
overexpressing cases.
MicroRNA expression proﬁles have also recently been investigated and highlighted the enrichment of different sets of microRNA in
the various PTCL subtypes when compared to normal mature T-cells [74]. A microRNA-based classiﬁer was then developed that was able
to assign each PTCL case to its correct subgroup with 97.5% concordance when compared with other molecular classiﬁers, suggesting that
the use of microRNA proﬁling may improve the diagnosis and classiﬁcation of PTCL.
6. Mutational spectrum
Different groups have recently investigated the mutational landscape of PTCL by NGS approaches, mainly whole exome sequencing
(WES). Among ALCL and AITL, different genes were reported to be recurrently mutated [7,11,13–15,75]. In ALK-neg ALCL, Crescenzo et al.
recently published a comprehensive characterization of driver genetic alterations converging to STAT3 activation, providing evidence that
inhibition of STAT3 has therapeutic eﬃcacy in vivo [11]. Speciﬁcally, STAT3 could be activated by direct mutations and/or JAK1 mutations
in ~20% ALK-neg ALCL. In JAK1/STAT3 WT cases, RNAseq analysis identiﬁed novel recurrent oncogenic translocations where the 3’ end of
the tyrosine kinases ROS1 or TYK2 was fused to the 5’ portion of NFkB2, NCOR2 or PABPC4 (all genes with high expression levels in T-cells),
resulting in oncogenic STAT3 activation. Interestingly, these recurring alterations were not found in PTCL NOS with overexpression CD30+
that shared morphological and phenotypic features with ALK-neg ALCL.
Among AITL patients, recent studies surprisingly described mutations in genes previously involved in myeloid malignancies: TET2 (70%),
a methylcytosine dioxygenase that catalyzes the conversion of methylcytosine to 5-hydroxymethylcytosine, DNMT3A (26%), a DNA
methyltransferase, and IDH2 (30%), an enzyme of the Krebs cycle that produces a TET2-inactivating oncometabolite whenmutated [13–15,75].
While this suggests a common theme of DNA methylation as a recurrently affected pathway across hematological malignancies, these
mutations tended to frequently co-occur in the same patient in PTCL, differently fromwhat previously reported for example inmyelodisplastic
syndromes [76,77]. In addition, mutations in RHOA, a member of the Rho family of small GTPases that control the cytoskeleton actin, were
identiﬁed in 50–70% of patients affected by AITL (Table 5). Interestingly, RHOA and IDH2 mutations where found at lower allelic frequen-
cies and in tumor cells only, while co-occurring TET2 and DNMT3Amutations were also found in white cells not belonging to the lymphoma
clone [14]. This suggests an intriguing multi-step tumorigenesis process where ﬁrst TET2 and/or DNMT3Amutations at the progenitor level/
stem cell level drive the expansion of a hematopoietic clone, likely of the same nature as those recently described in age-related clonal
hematopoiesis [78–80]. This would create a favorable genetic background in mature clonal T-lymphocytes for the development of
Fig. 3. Hypothetical cell-of-origin model for PTCL-NOS based on gene expression data.
14 F. Maura et al./Pathogenesis 3 (2016) 9–18
subsequent RHOA mutations that can then divert the phenotype toward a PTCL, similar to what happens in AML where NPM1 mutations
are thought act at in a similar way downstream of pre-existing, non-clinically apparent mutations (Fig. 4) [81].
A similar mutational proﬁle to AITL was also detected in the small number of PTCL-NOSs analyzed by WES (n = 6), and in subsequent
extension cohorts (n = 44) by candidate targeted sequencing [13]. Speciﬁcally, 48.5%, 17.2% and 27.3% of PTCL-NOS samples harbored TET2,
RHOA and DNMT3A mutations, respectively, and similar to AITL, all these mutations frequently co-occurred in the same patients. On the
contrary, no IDH2 mutations were initially described among PTCL-NOSs [13]. A comparable mutational spectrum was found in GATA3 and
TBX21 GEP subgroups, thus not providing any insight on the causal relation between the tumor genotype and its expression proﬁle [82].
Interestingly, 13 of 15 PTCL-NOS cases harboring RHOA mutations were characterized by an AITL-like phenotype and had a T-follicular
helper gene expression proﬁle [83]. Furthermore, IDH2 mutational analysis of the large PTCL cohort annotated by GEP [12] showed that
IDH2 mutations were frequent in PTCL-NOS reclassiﬁed as AITL (4/11) but almost absent in AITL reclassiﬁed as PTCL-NOS (1/14). In ret-
rospect, it is likely that the presence of PTCL NOS cases with TFH proﬁle, which are now known to share more biological and pathological
features with AITL than with PTCL-NOS, was responsible for the asymmetric exchange of IDH2 mutated patients between PTCL-NOS and
AITL prompted by gene expression proﬁling [33,39,70]. Together, these data suggest that the TFH PTCL-NOS subgroup shares genomic as
well as phenotypic features with AITL more than it does with PTCL-NOS, and stresses the challenges of the current PTCL histologic clas-
siﬁcation (Fig. 3).
In light of the above, no speciﬁc and recurrent mutations have been found in PTCL-NOS by WES so far. This was recently challenged
by a targeted deep sequencing approach for candidate driver gene mutations in a series of 28 PTCL-NOS samples that excluded cases with
AITL features [84]. With the limitations of a gene-discovery analysis based on a prespeciﬁed list of candidate drivers without matched
germline DNA, the report highlighted frequent mutations in genes related to epigenetics. Regulators of histone methylation were mutated
in 25% of cases, including mutations in KMT2D (4/28 cases), KDM6A (3/28) and KMT2A (2/28), and were associated with a poorer survival.
Regulators of DNA methylation were also affected in 25% of cases, including TET2 (3 cases) and DNMT3A (2 cases). Moreover, genes related
to chromatin remodeling mediated by the SWI/SNF complex activity were mutated in 18% of cases and 46% of the cases, respectively. (Table 5).
Table 5
Mutational landscape of AITL and PTCL-NOS according with recent next generation sequencing data.
Ref RHOA TET2 DNMT3A IDH2
AITL PTCL-NOS AITL PTCL-NOS AITL PTCL-NOS AITL PTCL-NOS
[15] 53.3% 7.7% nd nd nd nd nd nd
(24/45) (1/13)
[13] 67% 18% 73% 29% 23% 12% 13% 0%
(22/35) (8/44) (22/30) (5/17) (7/30) (2/17) (4/30) (0/17)
[14] 71% 17% 82.6% 48.5% 26% 27.3% 30.5% 0%
(51/72) (15/87) (38/46) (16/33) (12/46) (9/33) (14/46) (0/33)
[82] 71.8% 27% 59% 46% 38.5% 36.6% 33% 4%
(28/39) (11/41) (23/39) (19/41) (15/39) (15/41) (19/58) (1/24)
Fig. 4. Hypothetical model of T-cell lymphomagenesis based on recent mutational discoveries.
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7. Conclusions and future perspectives
Thanks to the availability of novel, often high-throughput analysis techniques, in the last decades we moved from a purely morpho-
logical description of PTCL cases to a much deeper understanding of their intrinsic biology. This has revealed that AITL and ALK-neg ALCL
have a fairly homogeneous set of genotypic and phenotypic features, justifying their existence as distinct clinico-pathological entities [11–15].
However, PTCL-NOSs are still regarded to as a heterogeneous category encompassing every PTCL case that does not ﬁt into other speciﬁc
subtypes. As such, the group of PTCL-NOS is an interesting ﬁeld of research either to ﬁnd unifying features of its cases, or to resolve its
heterogeneity into several distinct and more homogeneous subgroups. On this note, it is encouraging to observe how the existence of a
subset of PTCL-NOS that have a follicular appearance and share morphologic and phenotypic features with AITL [85] has more recently
been substantiated by the ﬁnding that such cases, grouped into the term TFH PTCL-NOS, are characterized by distinct cytogenetic, transcriptomic
and genomic features that suggest they should be assigned to a distinct entity. We therefore believe that, given the similarities between
TFH PTCL-NOS and AITL, the former subgroup should be excluded from future PTCL-NOS studies, as its inclusion could introduce a con-
founding factor and hamper the correct interpretation of the results. While we are gaining insight into those groups that show the most
distinctive features, it will be harder to ﬁnd relevant information on the residual cases that still lack unifying features. In the future, an
integrated approach looking at the whole constellation of genomic features (mutations, structural variants, and mutational signatures),
expression proﬁles and clinical outcomes of PTCL-NOS will hold the promise of shedding some light into this subgroup of PTCLs. Only
such large-scale efforts have the potential to inform on the complex biology of such cases, providing rationale bases for a novel classiﬁ-
cation of PTCL based on real clinico-pathological entities, and possibly to provide novel prognostic markers and therapeutic targets.
While the recent advances described here have not yet translated into advances in clinical practice, it is likely that in the near future,
speciﬁc gene mutation or expression patterns will be harnessed as novel diagnostic tests to overcome diagnosis issues related to cases
not univocally classiﬁed on morphological grounds. As an example, the search for RHOA and IDH2 mutations is already performed in some
laboratories to distinguish AITL from PTCL-NOS. Furthermore, as increased GATA3mRNA expression correlates with a poor prognosis, efforts
are underway to validate standardized IHC methods to predict outcome of PTCL-NOS from routine trephines based on the expression of
the GATA3 protein.
PTCL-NOS remains an aggressive disease with a poor survival [1]. Conventional chemotherapy approaches explored so far, including
upfront autologous stem cell transplant, resulted in an unsatisfactory improvement of survival [3,86,87]. The use of novel, targeted treat-
ments in PTCL has shownmixed results (Table 6) [30,88–96]. Nevertheless, biological evidence supporting the use of these novel therapeutic
agents is lacking, and promising responses are admixed with complete failures. The future identiﬁcation of recurrent genomic aberra-
tions and aberrantly activated oncogenic pathways will thus help the clinician to prioritize novel targeted approaches to be validated in
prospective trials, and provide markers of response that could inform on the best treatment approach in individual patients.
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